共查询到12条相似文献,搜索用时 0 毫秒
1.
2.
Carla L. Dinardo Theo G. M. Oliveira Shannon Kelly Allison Ashley-Koch Marilyn Telen Luciana C. Schmidt Shirley Castilho Karla Melo Marcia R. Dezan Marsha M. Wheeler Jill M. Johnsen Deborah A. Nickerson Deepti Jain Brian Custer Alexandre C. Pereira Ester C. Sabino for the NHLBI Recipient Epidemiology Donor Evaluation Study International Component-Brazil the Outcome Modifying Genes in SCD study the NHLBI Trans-Omics for Precision Medicine Program Sickle Cell Disease Working Group 《Transfusion》2021,61(2):603-616
3.
4.
5.
Kazutaka Suzuki Keiki Nagaharu Mitsuko Maruyama Takeshi Matsumoto Kohshi Ohishi Isao Tawara 《Transfusion》2023,63(4):867-871
Background
Cisplatin-associated hemolysis is a rare but important adverse effect. Nonimmunological protein adsorption (NIPA) due to erythrocyte membrane modification has been reported as the leading cause of cisplatin-associated hemolysis. However, limited data exist on cisplatin-associated immunological hemolysis because of a lack of an established diagnostic method. Here, we used flow cytometry (FCM) to diagnose a patient with cisplatin-associated immunological hemolysis.Study Design and Methods
A 55-year-old woman with uterocervical cancer was treated with weekly cisplatin monotherapy (40 mg/m2). She had no previous transfusion and medication history, nor any significant family history. On the 26th day after cisplatin administration, severe hemolysis was noted. Her red blood cells (RBCs) and sera were evaluated by direct antiglobulin test (DAT) and indirect antiglobulin test (IAT), respectively. To explore immunological reactions for cisplatin-treated RBCs, we attempted FCM using cisplatin-treated and -untreated RBCs. After incubating conditioned RBCs with the patient's serum or healthy donor serum, we evaluated their fluorescent intensity by fluorescein isothiocyanate (FITC)-conjugated anti-human immunoglobulin (Ig) G antibodies.Results
The patient's DAT was positive, and an IAT using her plasma was positive for cisplatin-treated RBCs. FCM using cisplatin-treated RBCs revealed that the patient's serum had higher FITC intensity than the donor's serum, indicating the existence of cisplatin-treated RBC-specific IgGs in patient's serum.Conclusion
Here, we report a rare case of a patient with hemolysis diagnosed using FCM to identify specific antibodies against cisplatin-treated RBCs. NIPA and immunological mechanisms may contribute to hemolysis onset during cisplatin treatment. 相似文献6.
7.
8.
9.
10.
M. Cyr H.A. Hume M. Champagne J.D. Sweeney C. Blais Jr . N. Gervais A. Adam 《Transfusion》1999,39(10):1084-1088
BACKGROUND: Severe hypotensive reactions have been described after the transfusion of platelets or red cells through negatively-charged bedside white cell-reduction filters. The possibility of a role for bradykinin (BK) in the genesis of these reactions has been raised. STUDY DESIGN AND METHODS: To understand if an anomaly of BK metabolism is associated with these reactions, the metabolism of BK and des-Arg9-BK was studied in the sera of four patients who presented with a severe hypotensive transfusion reaction. Tests were performed in the absence and the presence of complete in vitro inhibition of angiotensin-converting enzyme (ACE) activity by enalaprilat. RESULTS: In the presence of ACE inhibition (enalaprilat), the half-life (t1/2) of BK measured in the sera of patients who presented with a severe hypotensive transfusion reaction (361 +/- 90 sec) was not significantly different from that measured in the sera of normal controls (249 +/- 16 sec). In the presence of ACE inhibition (enalaprilat), the t1/2 of des-Arg9-BK was significantly greater in patients who presented with a severe hypotensive transfusion reaction (1549 +/- 319 sec) than in normal controls (661 +/- 38 sec) (p < 0.001). CONCLUSION: A metabolic anomaly mainly affecting the degradation of des-Arg9-BK could be responsible for its accumulation in vivo. Des-Arg9-BK could be responsible, at least in part, for severe hypotensive transfusion reactions. 相似文献